ClinicalTrials.gg
CompletedNCT05695417Updated Nov 19, 2026

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

A Phase 1 interventional study of OTX-TKI and Sham in Non-proliferative Diabetic Retinopathy, sponsored by Ocular Therapeutix, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Ocular Therapeutix, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.
Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
145th of 196
22 · median 72
Started
2023
with 11 others
Phase 1
29 of 267
4 open now
Registered
213th of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 145th largest by enrollment of the 196 interventional ones that give a count, is one of 12 that started in 2023, is one of 29 in phase 1, and was the 213th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Read the detailed description

Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (axitinib implant) for Intravitreal Injection in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

03

Conditions studied

  • Non-proliferative Diabetic Retinopathy

Browse trials for

Keywords

  • Nonproliferative diabetic retinopathy
  • Diabetic retinopathy OTX-TKI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are at least 18 years of age or older
  • Moderately severe to severe NPDR in the study eye defined as: DRSS levels of 47 or 53 as determined by the reading center
  • Diabetes type 1 or 2
  • BCVA ETDRS letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)

Exclusion criteria

Exclusion Criteria:

  • DME within 6 months involving the center of the macula in the study eye
  • Presence of DME threatening the center (within 200 microns) of the macula in the study eye
  • OCT CSFT of ≥320 μm in the study eye
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Active comparator
    OTX-TKI

    Drug: OTX-TKI

  • Sham comparator
    Sham

    Drug: Sham

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Frequency of treatment emergent adverse events

    Time frame: Baseline up to Week 52

Secondary outcomes

  1. Change in Best Corrected Visual Acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score

    Best Corrected Visual Acuity (BCVA) changes from baseline

    Time frame: Baseline up to Week 52

  2. Central subfield thickness changes

    Central subfield thickness changes from baseline

    Time frame: Baseline up to Week 52

  3. Rescue Therapy

    Proportion of subjects receiving rescue therapy

    Time frame: Baseline up to Week 52

  4. Diabetic Retinopathy Severity Scale (DRSS) changes

    Diabetic Retinopathy Severity Scale (DRSS) changes from baseline

    Time frame: Baseline up to Week 52

07

Study locations

10 sites
  • Ocular Therapeutix Inc
    Phoenix, Arizona 85053, United States
  • Ocular Therapeutix, Inc.
    Bakersfield, California 93308, United States
  • Ocular Therapeutix, Inc.
    Augusta, Georgia 30909, United States
  • Ocular Therapeutix, Inc.
    Lemont, Illinois 60439, United States
  • Ocular Therapeutix, Inc.
    Hagerstown, Maryland 21740, United States
  • Ocular Therapeutix, Inc.
    Reno, Nevada 89502, United States
  • Ocular Therapeutiux, Inc.
    Austin, Texas 78750, United States
  • Ocular Therapeutix Inc
    Bellaire, Texas 77401, United States
  • Ocular Therapeutix, Inc
    San Antonio, Texas 78211, United States
  • Ocular Therapeutix Inc.
    The Woodlands, Texas 77384, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2023 to primary completion in May 2024, 16 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jan 2024 → May 2024 and completion Dec 2024 → Jul 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2023
First posted
Jan 25, 2023
StartActual
Jan 15, 2023
Primary completionActual
May 28, 2024was Jan 2024
CompletionActual
Jul 12, 2024was Dec 2024
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 19, 2026
Primary completion
Jan 2024→May 28, 2024 (actual)
Nov 19, 2026
Study completion
Dec 2024→Jul 12, 2024 (actual)
Nov 19, 2026
Enrollment
21 (estimated)→22 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Active, not recruiting→Completed
    Primary completion Jan 2024→May 28, 2024 (now actual)
    Study completion Dec 2024→Jul 12, 2024 (now actual)
    Enrollment 21 (estimated)→22 (actual)
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05695417
Responsible party
Sponsor
First posted
Jan 25, 2023
Start date
Jan 15, 2023
Primary completion
May 28, 2024
Completion
Jul 12, 2024
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion